6 employees
Yamo Pharmaceuticals is a clinical-stage pharmaceutical company that develops L1-79, a novel therapy for Autism spectrum disorder.
2015
Yamo Pharmaceuticals raised undisclosed on November 10, 2021
Investors: Autism Impact Fund